NewsBenzingaGSKのVelzatinib、GISTに対する日本の希少疾病用医薬品指定を取得、StrateGIST 1データにより裏付けられる;米FDAファストトラック指定、米国・欧州のODD、進行中の第III相試験に追加 GSKのVelzatinib、GISTに対する日本の希少疾病用医薬品指定を取得、StrateGIST 1データにより裏付けられる;米FDAファストトラック指定、米国・欧州のODD、進行中の第III相試験に追加 Benzinga 2026.11.19 07:50 (GMT+0) Open on Benzinga Other news Meta Halts Mark Zuckerberg’s New Share Issuance Plan Amid Investor Lawsuit Alleging CEO Pressured Board to Approve It Sunlands Technology Q3 EPS $0.41 Down From $1.31 YoY, Sales $49.500M Down From $73.472M YoY Anthropic IPO to Mint Thousands of Millionaires, With Seven Founders Becoming $10 Billion-Plus Billionaires Futu Holdings Q3 Sales $852.660M Beat $814.820M Estimate ATRenew Q3 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $962.500M Beat $944.000M Estimate GSK’s Velzatinib Receives Japan Orphan Drug Designation For GIST, Supported By StrateGIST 1 Data; Adds To US FDA Fast Track, US, EU ODDs, Phase III Trials Under Way
Meta Halts Mark Zuckerberg’s New Share Issuance Plan Amid Investor Lawsuit Alleging CEO Pressured Board to Approve It
Anthropic IPO to Mint Thousands of Millionaires, With Seven Founders Becoming $10 Billion-Plus Billionaires
GSK’s Velzatinib Receives Japan Orphan Drug Designation For GIST, Supported By StrateGIST 1 Data; Adds To US FDA Fast Track, US, EU ODDs, Phase III Trials Under Way